NCT01128556View on ClinicalTrials.gov

The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Histamine Responsive Allergy Patients
Interventions
DRUG

Bepreve

Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily

DRUG

Refresh Tears

Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment

Trial Locations (1)

76132

North Texas Institute for Clinical Trials, Fort Worth

Sponsors
All Listed Sponsors
lead

North Texas Institute for Clinical Trials

OTHER

NCT01128556 - The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing | Biotech Hunter | Biotech Hunter